Prostate Cancer

>

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Latest News

Christian Rommel, PhD
Darolutamide Plus ADT Provides Statistically Significant rPFS Advantage in mHSPC

July 17th 2024

Darolutamide plus ADT improved radiologic PFS vs placebo plus ADT in men with metastatic hormone-sensitive prostate cancer enrolled in the phase 3 ARANOTE trial.

Rahul Aggarwal, MD, of UCSF Helen Diller Family Comprehensive Cancer Center
Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

July 11th 2024

US FDA
FDA Grants Fast Track Designation to BNT324/DB-1311 in mCRPC

July 8th 2024

S. Lindsey Davis, MD, oncologist, University of Colorado Cancer Center; associate professor, medicine-medical oncology, University of Colorado Anschutz Medical Campus
The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

FDA
FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

July 1st 2024

Video Series
Video Interviews
Podcasts
Neeraj Agarwal, MD
Andrew J. Armstrong, MD, MSc
Michael C. Haffner, MD, PhD
Amar U. Kishan, MD
Latest CME Events & Activities

Everything You Need to Know About PARP Inhibitor Combinations in Prostate Cancer Care: Why? For Whom? And When?

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Advances In™: Targeting PSMA to Advance Diagnosis And Management Of Patients With Prostate Cancer

View More

Clinical Case Vignette Series: Integrating Recent Data into Practice to Improve Outcomes in Advanced Prostate Cancer

View More

Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease

View More

2023 ASCO Direct™ Highlights: Practice-Changing Data From the Leading Oncology Conference

View More

Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board

View More

Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?

View More

Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!

View More

Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer

View More

Dialogues With the Surgeon on Integration of Systemic Therapies in Perioperative Settings for NSCLC: Looking at EGFR, ALK, IO, and Beyond…

View More

Tumor-Infiltrating Lymphocyte Therapy Advances Into Melanoma

View More

More News